Similar articles

• Blood-pressure reduction with LCZ696, a novel dual-acting inhibitor of the angiotensin II receptor and neprilysin: a randomised, double-blind, placebo-controlled, active comparator study.

  Ruilope LM, Dukat A, Böhm M, Lacourcière Y, Gong J, Lefkowitz MP. Ruilope LM, et al. Lancet. 2010 Apr 10;375(9722):1255-66. doi: 10.1016/S0140-6736(09)61966-8. Epub 2010 Mar 16. Lancet. 2010. PMID: 20236700 Clinical Trial.
• Efficacy and Safety of Crystalline Valsartan/Sacubitril (LCZ696) Compared With Placebo and Combinations of Free Valsartan and Sacubitril in Patients With Systolic Hypertension: The RATIO Study.

  Izzo JL Jr, Zappe DH, Jia Y, Hafeez K, Zhang J. Izzo JL Jr, et al. J Cardiovasc Pharmacol. 2017 Jun;69(6):374-381. doi: 10.1097/FJC.0000000000000485. J Cardiovasc Pharmacol. 2017. PMID: 28338503 Clinical Trial.
• Modulation of 24-h blood pressure profiles: a new target for treatment?

  Palatini P, Parati G. Palatini P, et al. J Hypertens. 2005 Oct;23(10):1799-801. doi: 10.1097/01.hjh.0000183121.69585.f1. J Hypertens. 2005. PMID: 16148601 No abstract available.
• Dual-acting angiotensin receptor-neprilysin inhibition.

  Segura J, Ruilope LM. Segura J, et al. Curr Hypertens Rep. 2011 Feb;13(1):74-8. doi: 10.1007/s11906-010-0166-7. Curr Hypertens Rep. 2011. PMID: 21046489 Review.
• Hope in Life and Value of blood pressure control.

  Ruilope LM, Segura J. Ruilope LM, et al. J Hypertens. 2004 Dec;22(12):2265-6. doi: 10.1097/00004872-200412000-00005. J Hypertens. 2004. PMID: 15614017 Review. No abstract available.